Fosamax Formulary Analysis: Health Plans Shift Tiers Or Delete Brand
A number of major health insurers are in the process of moving Merck's Fosamax (alendronate) to higher cost-sharing tiers or off formularies altogether following the recent launch of generic competitors
You may also be interested in...
So far GlaxoSmithKline's Avandia (rosiglitazone) appears to be retaining its tier 2 status on the 2008 formularies of major Medicare Part D plans despite safety concerns that surfaced earlier this year
The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward
Bipartisan congressional letters seek relief from HHS but the Trump Administration has taken aim at 340B providers itself and may not be inclined to help.